Alimera Sciences

ALIM NASDAQ
0.9246
+0.0046
+0.50%
Closed 16:00 06/14 EDT
Open
0.9120
Prev Close
0.9200
High
0.9327
Low
0.9011
Volume
59.50K
Avg Vol (3M)
91.05K
52 Week High
1.210
52 Week Low
0.7181
% Turnover
0.08%
Market Cap
65.65M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Alimera Sciences ALIM stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
MORE >

Recently

Name
Price
%Change